Implanted devices (joints, catheters, stents, pacemakers, etc) provide a solid surface for bacterial growth upon which biofilms quickly form. A typical infection can cost as much as US$47,000 per patient to treat, and costs escalate with chronic, recurrent infections.
Biofilms cause over 2 million infections annually, resulting in an estimated US$11B in additional patient healthcare costs. Hospital acquired infections cost US$1.8B annually with urinary catheter use associated with up to 90% of these infections.
Innovotech technology and expertise provides medical device manufacturers an accepted approach to first, evaluate anti-microbial/anti-adherence biofilm coatings to study biofilm disease and then, to develop research studies to validate product efficacy claims suitable for regulatory submission. The company has worked with clients to achieve 510K approval in less than 12 months, owing to the high throughput nature of the company’s in vitro technology.